Scope
Reference
C402343
Description
CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient's T cells are genetically modified to target cancer cells.
The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products
At the time of writing it is only offered at 8 sites across the UK.
The proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order.
The price paid to the supplier with be capped at NICE / NHS England approved list prices.
Contract 1. Provision of CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) products
Supplier
Contract value
- £2,100,000 excluding VAT
- £2,520,000 including VAT
Above the relevant threshold
Earliest date the contract will be signed
8 December 2025
Contract dates (estimated)
- 8 December 2025 to 5 December 2030
- Possible extension to 7 December 2035
- 10 years
Description of possible extension:
Option to extend contract by a further 5 years
Main procurement category
Services
Options
The right to additional purchases while the contract is valid.
Extension option
CPV classifications
- 33000000 - Medical equipments, pharmaceuticals and personal care products
- 85149000 - Pharmacy services
Other information
Conflicts assessment prepared/revised
Yes
Procedure
Procedure type
Direct award
Direct award justification
Single supplier - intellectual property or exclusive rights
CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient's T cells are genetically modified to target cancer cells.
The products can only be supplied by the the proposed contractor, Bristol Myers Squibb.
Supplier
Bristol Myers Squibb
- Companies House: 02487574
Arc Uxbridge Sanderson Road, New Denham,
Denham
UB8 1DH
United Kingdom
Email: jon.joyce@bms.com
Region: UKJ13 - Buckinghamshire CC
Small or medium-sized enterprise (SME): No
Voluntary, community or social enterprise (VCSE): No
Contract 1. Provision of CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) products
Contracting authority
Barts Health NHS Trust
- Public Procurement Organisation Number: PVTL-5832-LMDG
20 Churchill Place, Canary Wharf
London
E14 5HJ
United Kingdom
Email: oliver.watling@nhs.net
Website: https://www.bartshealth.nhs.uk
Region: UKI42 - Tower Hamlets
Organisation type: Public authority - central government